RecruitingNot ApplicableNCT04312399
Hormone Replacement Trial Against ALzheimers' Disease
Sponsor
University Hospital, Ghent
Enrollment
600 participants
Start Date
Apr 17, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.
Eligibility
Sex: FEMALEMin Age: 40 YearsMax Age: 65 Years
Inclusion Criteria2
- postmenopausal women
- years
Exclusion Criteria6
- Longer than 10 years in menopause
- thyroid dysfunction
- hypertension
- medical history of psychiatric comorbidity
- Alcohol and/or drug abuse
- medical history of neurologic symptoms with cognitive symptoms
Interventions
PROCEDUREblood take
Blood is taken to analyse degradation products of the metabolism of amyloid
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04312399
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT066577689 locations